Last reviewed · How we verify
Dalbavancin via Intraperitoneal Administration
Dalbavancin is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.
Dalbavancin is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors. Used for Intra-abdominal infections via intraperitoneal administration, Peritonitis in peritoneal dialysis patients.
At a glance
| Generic name | Dalbavancin via Intraperitoneal Administration |
|---|---|
| Sponsor | University of Colorado, Denver |
| Drug class | Lipoglycopeptide antibiotic |
| Target | Bacterial peptidoglycan (D-Ala-D-Ala) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Dalbavancin works by disrupting the cross-linking of peptidoglycan in bacterial cell walls, similar to vancomycin but with enhanced potency and a longer half-life. When administered intraperitoneally, it achieves high local concentrations in the peritoneal cavity to treat intra-abdominal infections. The intraperitoneal route allows direct delivery to the infection site while minimizing systemic exposure.
Approved indications
- Intra-abdominal infections via intraperitoneal administration
- Peritonitis in peritoneal dialysis patients
Common side effects
- Infusion-related reactions
- Local peritoneal irritation
- Elevated liver enzymes
- Renal impairment
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: